Vilobelimab
Vilobelimab is an antibody pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gohibic | Use Authorization | 2025-01-23 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
179 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | — | C34.90 | 13 | 21 | 11 | 1 | — | 40 |
| Non-small-cell lung carcinoma | D002289 | — | — | 11 | 21 | 11 | 2 | — | 39 |
| Oropharyngeal neoplasms | D009959 | — | — | 2 | 7 | 4 | 1 | — | 13 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 11 | 23 | 12 | — | 2 | 46 |
| Squamous cell carcinoma | D002294 | — | — | 8 | 20 | 6 | — | 2 | 36 |
| Uterine cervical neoplasms | D002583 | — | — | 9 | 12 | 7 | — | — | 26 |
| Adenocarcinoma | D000230 | — | — | 6 | 9 | 8 | — | — | 22 |
| Esophageal neoplasms | D004938 | — | C15 | 3 | 16 | 5 | — | 2 | 22 |
| Adenosquamous carcinoma | D018196 | — | — | 6 | 5 | 6 | — | — | 17 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 6 | 6 | 3 | — | — | 15 |
| Head and neck neoplasms | D006258 | — | — | 4 | 6 | 2 | — | — | 12 |
| Squamous cell neoplasms | D018307 | — | — | 5 | 4 | 3 | — | — | 12 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 6 | 3 | — | 2 | 11 |
Show 27 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 3 | 6 | — | — | — | 7 |
| Small cell lung carcinoma | D055752 | — | — | 4 | 2 | — | — | — | 6 |
| Urinary bladder neoplasms | D001749 | — | C67 | — | 4 | — | — | 1 | 5 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 5 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
| Central nervous system neoplasms | D016543 | — | — | — | 3 | — | — | — | 3 |
| Nervous system neoplasms | D009423 | — | — | — | 3 | — | — | — | 3 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | — | 2 | — | — | — | 2 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | — | — | 2 |
| Granulomatosis with polyangiitis | D014890 | EFO_0005297 | M31.3 | — | 2 | — | — | — | 2 |
Show 44 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell carcinoma | D018288 | — | — | 2 | — | — | — | — | 2 |
| Mouth neoplasms | D009062 | EFO_0003868 | C06.9 | 1 | — | — | — | — | 1 |
| Verrucous carcinoma | D018289 | — | — | 1 | — | — | — | — | 1 |
| Paranasal sinus neoplasms | D010255 | — | — | 1 | — | — | — | — | 1 |
| Mucositis | D052016 | EFO_1001898 | — | 1 | — | — | — | — | 1 |
| Laryngeal diseases | D007818 | — | J38.7 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fever | D005334 | — | R50.9 | — | — | — | — | 1 | 1 |
| Hyperthermia | D000084462 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vilobelimab |
| INN | vilobelimab |
| Description | CaCP29 (mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109636 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB16416 |
| UNII ID | F5T0RF9ZJA (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 362 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use